Literature DB >> 27283596

[Eclipse retinopathy : A case series after the partial solar eclipse on 20 March 2015].

I Bachmeier1, H Helbig2, R Greslechner2.   

Abstract

BACKGROUND: Solar retinopathy refers to damage to the central macula caused by exposure to intense solar radiation, most frequently observed after a solar eclipse.
OBJECTIVE: Description of the morphological changes in spectral domain optical coherence tomography (SD-OCT) and the clinical course in patients with acute solar retinopathy.
MATERIAL AND METHODS: The study included a retrospective analysis of 12 eyes from 7 patients with solar retinopathy after the partial solar eclipse on 20 March 2015. Best corrected visual acuity, fundus changes and SD-OCT findings were analyzed. Out of the 7 patients 5 underwent treatment with 1 mg prednisolone per kg body weight.
RESULTS: The average age of the patients was 30.1±13.1 years. Best corrected visual acuity was 0.65 at initial presentation. In the acute stage all affected eyes showed a small yellowish lesion in the centre of the fovea in the fundoscopic examination. In SD-OCT the continuity of all layers in the foveola appeared disrupted. In the follow-up examination these changes were partially resolved. After 2 months SD-OCT revealed a small defect of the ellipsoid zone. In one patient the defect could not be shown due to slightly excentric imaging sections. Best corrected visual acuity increased to 0.97.
CONCLUSION: The SD-OCT is an appropriate tool to determine the exact localization of the site of damage and for follow-up examination in solar retinopathy. In the acute phase it shows a disruption of the continuity of all layers in the foveola. Despite good recovery of visual acuity a small central defect of the ellipsoid zone remains in the long term.

Entities:  

Keywords:  Corticosteroid treatment; Macula; Optical coherence tomography; Solar retinopathy; Visual loss

Mesh:

Year:  2017        PMID: 27283596     DOI: 10.1007/s00347-016-0286-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  29 in total

1.  Optical coherence tomography findings in early solar retinopathy.

Authors:  M Bechmann; O Ehrt; M J Thiel; N Kristin; M W Ulbig; A Kampik
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  Solar retinitis.

Authors:  S Y SHIRLEY
Journal:  Can Med Assoc J       Date:  1963-07-20       Impact factor: 8.262

3.  Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus.

Authors:  Giovanni Staurenghi; Srinivas Sadda; Usha Chakravarthy; Richard F Spaide
Journal:  Ophthalmology       Date:  2014-04-19       Impact factor: 12.079

4.  Subtle solar retinopathy detected by fourier-domain optical coherence tomography.

Authors:  Ya-Hsin Kung; Tsung-Tien Wu; Shwu-Jiuan Sheu
Journal:  J Chin Med Assoc       Date:  2010-07       Impact factor: 2.743

5.  Retinal sensitivity to damage from short wavelength light.

Authors:  W T Ham; H A Mueller; D H Sliney
Journal:  Nature       Date:  1976-03-11       Impact factor: 49.962

6.  The human fovea after sungazing.

Authors:  M O Tso; F G La Piana
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1975 Nov-Dec

7.  Acute eclipse retinopathy: a small case series.

Authors:  Nur Khatib; Boris Knyazer; Tova Lifshitz; Jaime Levy
Journal:  J Optom       Date:  2014-01-22

8.  Methylprednisolone therapy in laser injury of the retina.

Authors:  T T Lam; K Takahashi; J Fu; M O Tso
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-12       Impact factor: 3.117

9.  Central serous chorioretinopathy complicating solar retinopathy treated with glucocorticoids.

Authors:  E A Bouzas; P Moret; C J Pournaras
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-02       Impact factor: 3.117

10.  OCT findings in patients with retinopathy after watching a solar eclipse.

Authors:  Marco Codenotti; Fabio Patelli; Rosario Brancato
Journal:  Ophthalmologica       Date:  2002 Nov-Dec       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.